Repeated Peripheral Infusions of Anti-EGFRvIII CAR T Cells in Combination with Pembrolizumab Show No Efficacy in Glioblastoma: A Phase I Trial

Investigators conducted a phase I trial of CAR T-EGFRvIII cells administered concomitantly with the anti-PD1 monoclonal antibody pembrolizumab in patients with newly diagnosed, EGFRvIII+ glioblastoma.